Clinical Trials Sponsored by Baker Heart Research Institute

Total 753 results

Baker Heart Research Institute

Completed

The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease

Peripheral Arterial Disease

Australia
Baker Heart Research Institute

Unknown

Cortisol and Nutritional Sympathetic Responsiveness

Obesity | Metabolic Syndrome | Insulin Resistance

Australia
Baker Heart Research Institute

Unknown

The Effects of Weight Loss on Neuroadrenergic Function

Obesity | Metabolic Syndrome | Type 2 Diabetes

Australia
Bayside Health
Baker Heart Research Institute

Completed

Improving Metabolism With HDL Cholesterol

Diabetes | Heart Disease

Australia
Baker Heart Research Institute
National Heart Foundation, Australia

Unknown

Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity

Metabolic Syndrome

Australia
Ottawa Heart Institute Research Corporation
Bayer

Completed

Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH

Chronic Thromboembolic Pulmonary Hypertension

Canada
Bayside Health
The Alfred; Baker Heart Research Institute

Completed

Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome

Marfan Syndrome
Baker Heart and Diabetes Institute

Recruiting

Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)

Heart Failure

Australia
Baker Heart and Diabetes Institute

Completed

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

Diabetic Nephropathies

Australia
Baker Heart and Diabetes Institute

Completed

Renal Denervation to Improve Outcomes in Patients With End-stage Renal Disease

Hypertension | End-stage Renal Disease

Australia
Baker Heart and Diabetes Institute

Completed

Sham Controlled Clinical Trial of Renal Denervation in Patients With Resistant Hypertension

Hypertension

Australia
Baker Heart and Diabetes Institute

Withdrawn

Renal Denervation for Uncontrolled Hypertension (RDNP-2012-02)

Hypertension
Baker Heart and Diabetes Institute

Terminated

Renal Denervation for Resistant Hypertension (RDNP-2012-01)

Hypertension

Australia
Baker Heart and Diabetes Institute

Completed

Polycystic Ovary Syndrome - Improving Outcomes

Polycystic Ovary Syndrome

Australia
Baker Heart and Diabetes Institute

Unknown

Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity

Obesity | Overweight

Australia
Baker Heart and Diabetes Institute

Unknown

The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

Hypertension | Abdominal Obesity

Australia
Baker Heart and Diabetes Institute

Not yet recruiting

Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor (Cog-HF)

Heart Failure | Cognitive Impairment | Dementia | Cognitive Change | Cognitive Decline | Left Ventricular Dysfunction
Baker Heart and Diabetes Institute

Completed

Effect of Ghrelin on Sympathetic Nervous System

Healthy | Obesity

Australia
Baker Heart and Diabetes Institute

Terminated

Renal Denervation for Complicated Hypertension (RDNP-2012-03)

Hypertension

Australia
Baker Heart and Diabetes Institute

Terminated

The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication

Peripheral Arterial Disease | Intermittent Claudication

Australia
Baker Heart and Diabetes Institute

Recruiting

Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)

Heart Failure

Australia
Baker Heart and Diabetes Institute

Recruiting

Early Detection of Coronary Artery Disease by Polygenic and Metabolic Risk Scoring (EDCAD-PMS)

Coronary Artery Disease

Australia
Baker Heart and Diabetes Institute

Withdrawn

Study of High Dosage of Losartan in Comparison to Low Dose of Losartan in Heart Failure Patients

Heart Failure
Bayside Health
Baker Heart Research Institute; International Diabetes Institute, Australia

Terminated

Type 2 Diabetes and Exercise - A Pilot Study

Type 2 Diabetes

Australia
Baker Heart Research Institute
National Health and Medical Research Council, Australia

Unknown

The Neurobiology of Depressive Illness

Major Depression

Australia
Baker Heart Research Institute
National Health and Medical Research Council, Australia

Unknown

Panic Disorder and Cardiac Risk

Panic Disorder

Australia
Bayside Health
Baker Heart and Diabetes Institute

Terminated

Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals

Central Arterial Pressure

Australia
Bayside Health
Baker Heart and Diabetes Institute

Unknown

Eplerenone in the Management of Abdominal Aortic Aneurysms

Aortic Aneurysm, Abdominal

Australia
Novartis Pharmaceuticals
Baker Heart and Diabetes Institute

Completed

Valsartan Intensified Primary Care Reduction of Blood Pressure Study (VIPER-BP)

Hypertension

United States, Australia
Ottawa Heart Institute Research Corporation
Bayer; Canadian Institutes of Health Research (CIHR); Biotronik Canada Inc

Active, not recruiting

Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial (OCEAN)

Stroke | Atrial Fibrillation

Canada, Australia, Germany, Belgium, China, Israel
Thrombosis Research Institute
Bayer

Completed

Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events (GARFIELD-VTE)

Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism

United States
Florida Heart Research Institute

Terminated

Study of Hispanics to Assess Risk Prevention in Prehypertension (SHARPP)

Pre-Hypertension

United States
Montreal Heart Institute
Ottawa Heart Institute Research Corporation

Completed

LVEF Prediction During ACS Using AI Algorithm Applied on Coronary Angiogram Videos (CathEF)

Acute Coronary Syndrome | Left Ventricular Dysfunction

Canada
Thrombosis Research Institute
Bayer

Completed

Rivaroxaban Evaluation in Real Life Settings (RIVER)

Stroke | Atrial Fibrillation

France, United Kingdom
Bayside Health
The Alfred; Baker Heart and Diabetes Institute

Unknown

Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment

Obesity | Cardiovascular Disease | Type 2 Diabetes

Australia
Karolinska Institutet
Region Stockholm; Australian Catholic University; Baker Heart and Diabetes Institute

Completed

Frequent Activity Snacks Breaks (FABS)

Obesity | Sedentary Lifestyle | Insulin Resistance

Sweden
The George Institute
Heart Research Institute

Recruiting

Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke (STARS)

Acute Ischemic Stroke

Australia
Population Health Research Institute
Bayer

Completed

Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial (ACTCOVID19)

Severe Acute Respiratory Syndrome | Coronavirus

Egypt, Canada, Brazil, Colombia, Ecuador, India, Nepal, Pakistan, Philippines, Russian Federation, South Africa, United Arab Emirates
Science Valley Research Institute
Bayer

Completed

Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients

Intermittent Claudication | Peripheral Artery Disease

Brazil
Lawson Health Research Institute
Bayer

Recruiting

Gadoxetate Abbreviated MRI in Metastatic Colorectal Cancer

Liver Metastasis Colon Cancer

Canada
Bayer
Population Health Research Institute

Completed

Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain. (PACIFIC-STROKE)

Acute Non-cardioembolic Ischemic Stroke

Spain, Japan, Australia, Czechia, Sweden, United Kingdom, Netherlands, Belgium, Russian Federation, Hungary, Slovakia, China, Germany, Switzerland, France, Poland, Denmark, United States, Austria, Bulgaria, Finland, Italy, Portugal
Ottawa Heart Institute Research Corporation

Not yet recruiting

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm (SEDATE)

Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Arrhythmias | Recurrent Ventricular Tachycardia
Ottawa Heart Institute Research Corporation

Recruiting

Florbetaben for Imaging of Vascular Amyloid (FERMATA)

Stroke | Transient Ischemic Attack | Acute Coronary Syndrome | Atherosclerosis of Artery

Canada
Ottawa Heart Institute Research Corporation

Recruiting

Reexamining Her Cardiovascular Risk - Ottawa WomeN's Longitudinal Cohort Study (HER-CROWN)

Cardiovascular Diseases

Canada
Ottawa Heart Institute Research Corporation

Not yet recruiting

Canagliflozin Targeting Vascular Inflammation (CANTORSING)

Coronary Artery Disease | Diabetes Type 2
Ottawa Heart Institute Research Corporation

Recruiting

Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock (MINOS)

Mitral Regurgitation | Cardiogenic Shock

United States, Canada
Ottawa Heart Institute Research Corporation

Recruiting

Effect of Colchicine on the Progression of Aortic Valve Stenosis - A Pilot Study (COPAS-Pilot)

Inflammation | Aortic Stenosis

Canada
Ottawa Heart Institute Research Corporation

Recruiting

An Evaluation of the Talk Test for Exercise Prescription for Home-Based Cardiac Rehabilitation (Talk-Test)

Coronary Artery Disease

Canada
Ottawa Heart Institute Research Corporation

Recruiting

Catheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial (CARA-VT RCT)

Ventricular Tachycardia

Canada
Ottawa Heart Institute Research Corporation

Recruiting

REvascularization and Valve Intervention for Ischemic Valve diseasE: REVIVE Trial (REVIVE)

Coronary Artery Disease | Mitral Valve Insufficiency

Canada

Clinical Trials Sponsored by Baker Heart Research Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations